Bioimpedance Analyzers Market Size

Bioimpedance Analyzers Market Analysis

The Bioimpedance Analyzers Market size is estimated at USD 568.43 million in 2024, and is expected to reach USD 910.48 million by 2029, growing at a CAGR of 9.88% during the forecast period (2024-2029).

The COVID-19 pandemic was expected to have a significant impact on market growth. This was mainly due to the high risk of obesity during the pandemic period. For instance, according to the article published in Diabetes Obesity and Metabolism in August 2021, obesity prevalence is a significant and potentially modifiable risk factor among COVID-19 patients. Therefore, the demand for bioimpedance analyzers is expected to increase as the risk of contracting COVID-19 remains high for obese patients. Additionally, due to changing lifestyles and an increase in home delivery, many individuals are consuming incredibly unhealthy prepared food. These behaviors could lead to an increase in body fat. Thus, rising obesity and related metabolic disorders among the population are expected to increase the demand for bioimpedance meters for precise assessment of muscle versus body fat and analyzing health risks associated with high fat in the body, thus expected to augment the market growth.

Certain factors that are propelling market growth are the increasing prevalence of metabolic disorders, rising government initiatives to promote healthy lifestyles, and emerging technological advancements.

The increasing incidences and prevalence of metabolic disorders such as diabetes, Gaucher's disease, glucose-galactose malabsorption, hereditary hemochromatosis, maple syrup urine disease (MSUD), phenylketonuria (PKU), and others are expected to be the major factor driving the demand for bioimpedance analyzers, thereby boosting the market growth. For instance, according to the International Diabetes Federation (IDF) data published in 2021, globally, there were 537 million people years affected by diabetes aged between 20-79 in 2021. Also, the same source mentioned that number of diabetes cases is expected to reach 783 million across the world. Additionally, the Gaucher's Institute article, updated in November 2021, reported that Gaucher's disease is equally prevalent in males and females and has a worldwide prevalence of 0.70 to 1.75 per 100,000 individuals annually. As per the same source, the standardized birth incidence of Gaucher's disease within the general population varies from 0.39 to 5.80 per 100,000 individuals annually. This disorder causes an inability to break down a certain type of fat, causing it to build up in the liver, spleen, and bone marrow, preventing the organs to work consistently. Thus, the disease can be clinically managed by incorporating an individualized nutrition assessment plan, considering the patient's energy requirements and mode of feeding. Therefore, the increasing burden of metabolic disorders is expected to increase the demand for bioimpedance analyzers owing to the effective management of the disorders, thereby fueling the market growth.

In addition, the rising government initiatives to promote a healthy lifestyle and achieve a healthy weight with improved well-being are also expected to boost market growth over the forecast period. For instance, in July 2021, the United Kingdom government launched National Health Service (NHS) Digital Weight Management Programme, which is supported by EUR 12 million (USD 12.75 million) in government funding. This program provides persons with obesity who are also diagnosed with diabetes, high blood pressure, or both free online support via referrals from a General Physician (GPs) and primary care teams.

Moreover, the rising technological advancements and increasing product launches are expected to boost the market's growth over the forecast period. For instance, in November 2021, BodyPedia launched its smart scale on Kickstarter, the body fat scale with 97% accuracy, to rehabilitate bioelectrical impendence analysis technology. This device provides accurate body composition report with body circumference to restore the reputation of bio-electrical impedance analysis technology.

However, inconsistency and inaccuracy in different analyzers are likely to restrain the market growth over the forecast period.